Essex Bio-Technology Ltd
HKEX:1061
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Essex Bio-Technology Ltd
Net Change in Cash
Essex Bio-Technology Ltd
Net Change in Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Essex Bio-Technology Ltd
HKEX:1061
|
Net Change in Cash
HK$225.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hbm Holdings Ltd
HKEX:2142
|
Net Change in Cash
$137.6m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
C
|
China Regenerative Medicine International Ltd
HKEX:8158
|
Net Change in Cash
HK$5.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Uni-Bio Science Group Ltd
HKEX:690
|
Net Change in Cash
HK$16.6m
|
CAGR 3-Years
4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CK Life Sciences Intl (Holdings) Inc
HKEX:775
|
Net Change in Cash
HK$241.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
S
|
SinoMab BioScience Ltd
HKEX:3681
|
Net Change in Cash
-¥52.6m
|
CAGR 3-Years
38%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
Essex Bio-Technology Ltd
Glance View
Essex Bio-Technology Ltd. is an investment holding company, which engages in the development, manufacture and sale of biopharmaceutical products. The company employs 1,379 full-time employees The company went IPO on 2001-06-27. The firm develops biopharmaceutical drugs based on recombinant deoxyribonucleic acid (DNA) technology. The main brands of the Company's products are Beifuji, Beifushu and Beifuxin. The firm operates through two business segments. The Pharmaceutical Products segment is engaged in the development, manufacture and sales of pharmaceutical products. The Provision of Marketing Services segment is involved in the distribution of third party products and provision of marketing services to such third party’s products.
See Also
What is Essex Bio-Technology Ltd's Net Change in Cash?
Net Change in Cash
225.6m
HKD
Based on the financial report for Dec 31, 2025, Essex Bio-Technology Ltd's Net Change in Cash amounts to 225.6m HKD.
What is Essex Bio-Technology Ltd's Net Change in Cash growth rate?
Net Change in Cash CAGR 5Y
12%
Over the last year, the Net Change in Cash growth was 377%.
